14hon MSN
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch
BioAtla’s Q3 2025 update details FDA-aligned Oz-V Phase III trial, peak sales forecast, strategic deal progress, and cost reductions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback